Gene Expressing Profiling of Iris Melanomas
Department of Ophthalmology & Visual Sciences, Washington University School of Medicine, St. Louis, Missouri.Ophthalmology (Impact Factor: 6.14). 01/2013; 120(1):213-213.e3. DOI: 10.1016/j.ophtha.2012.08.016
- [Show abstract] [Hide abstract]
ABSTRACT: PURPOSE: To evaluate outcomes after ophthalmic plaque radiation therapy for small choroidal melanomas. DESIGN: Retrospective study, case series. PARTICIPANTS: Seventy-two patients with choroidal melanomas ≥1.5 and ≤2.4 mm apical height and ≤10 mm width treated between 2002 and 2012, with a minimum follow-up of 8 months. METHODS: All patients were treated with palladium-103 plaque brachytherapy. Mean radiation dose to the tumor apex was 82.4 Gy (range, 70.0-102 Gy). MAIN OUTCOME MEASURES: Local control, radiation complications, visual acuity, and metastatic rate. RESULTS: Plaque radiotherapy provided 100% local tumor control and eye retention at a mean 54 months of observation (95% confidence interval, 46-63 months). The most common long-term brachytherapy-related complications were radiation maculopathy (43.1%) and radiation optic neuropathy (20.8%) developing at a mean of 27 months (range, 9-72 months) after irradiation. In this series, 94.4% of patients maintained 20/200 or better vision. There has been no small choroidal melanoma-related metastasis. CONCLUSIONS: Palladium-103 plaque radiation therapy offered excellent local control and visual acuity outcomes for patients with small choroidal melanoma. FINANCIAL DISCLOSURE(S): The author(s) have no proprietary or commercial interest in any materials discussed in this article.Ophthalmology 06/2013; 120(11). DOI:10.1016/j.ophtha.2013.04.017 · 6.14 Impact Factor
Data provided are for informational purposes only. Although carefully collected, accuracy cannot be guaranteed. The impact factor represents a rough estimation of the journal's impact factor and does not reflect the actual current impact factor. Publisher conditions are provided by RoMEO. Differing provisions from the publisher's actual policy or licence agreement may be applicable.